

Scientific Programme

Prague - June 11-14 2008

Wednesday, June 11		
18:30-22:00	Opening Ceremony ECFS Award Welcome reception	
Thursday, June 12		
07:30-08:15	Round tables	Terraces 1 and 2
	Managing Urinary Incontinence	M. Dodd (UK)
	Fertility and pregnancy	G. Thorpe-Beeston (UK)
	Infection control	F. Festini (IT)
	Gender differences	M. Wennstrom (SE)
	Survival analysis from registries. Methods and Pitfalls. Recording bias	J. Dodge (UK)
	DM and registries - relevant variables	K. Gyi (UK)
	Home IV therapy: who, how, legal issues	M. Proesmans (BE)
	CF at school	I. Sermet (FR)
	When to start treatment in a screened baby	A. Malfroot (BE)
	Exercise testing in children	H. Hebestreit (DE)
	Is it possible to decrease the burden of treatment?	I. Balfour-Lynn (UK)
	Difficult diagnosis	K. Southern (UK)
	Mechanisms of inflammation	G. Döring (DE)
	Interpretation of the laboratory genetic analysis report	C. Castellani (IT)
	Managing Constipation and DIOS	C. Taylor (UK)
	Optimising growth and nutritional status of CF infants	A. Munck (FR)
	Antibiotic resistance - does it matter?	J. Foweraker (UK)
	Use of microarrays in microbiology	P. Drevinek (CZ)
	Quorum sensing - prospects for new therapy	M. Givskov (DK)
	Mechanisms of lung disease in CF	M. Mall (DE)
	CFTR Structure: Why is it really important?	P. Lehn (FR)
Thursday, June 12		
08.30-10.00	Plenary I	Congress Hall
	Moderators: P. Pohunek (CZ) / S. Elborn (UK)	
	Translating Laboratory Discoveries to Patient Benefit: What do we still need to know to stop CF lung damage	
	CFTR Dysfunction – M. Amaral (PT) Infection – G. Döring (DE) Inflammation – F. Accurso (US) Options to treat - J. Davies (UK)	
10:00-10:30	Coffee	Exhibition Hall
Thursday, June 12		
10:30-12:00	Symposium 1 - Pulmonology	Congress Hall
	Pro/Con	
	Moderators: S. Bell (AU) / P. Pohunek (CZ)	
	Any child that does not produce sputum should undergo annual bronchoscopy - Pro – D. Armstrong (AU) - Con – B. Fauroux (FR)	
	Center care is best care - Pro – J. Barben (CH)	

Version (updated 3/14/2008)

	- Con - C. De Boeck (BE)	
Thursday, June 12		
	Symposium 2	Panorama Hall
10:30-12:00	Bacterial physiology in the niches of the CF lung Moderators: P. Drevinek (CZ) / C. Wolz (DE)	
	<i>Pseudomonas aeruginosa</i> - S. Molin (DK)	
	<i>S. aureus</i> - B. Kahl (DE)	
	<i>Burkholderia</i> - J. Govan (UK)	
	Aerobic-anaerobic niches - D. Worlitzsch (DE)	
Thursday, June 12		
	Symposium 3	Forum Hall
10:30-12:00	Cystic Fibrosis Related Diabetes Moderators: S. Conway (UK) / S. Kolouskova (CZ)	
	Pathophysiology: Mechanical or autoimmune impairment; insulinopenia or insulin resistance? - S. Nousia-Arvanitakis (GR)	
	CF related Diabetes; a major co-morbidity affecting lung function and survival - M. Ballmann (DE)	
	Diagnosis and medical management - S. Conway (UK)	
	The nutritional challenges of the patient with CFRD - A. Morton (UK)	
Thursday, June 12		
	Symposium 4	North Hall
10:30-12:00	Glands and mucus versus surface epithelium Moderators: M. Chanson (CH) / R. Tarran (US)	
	Control of the ASL and implications for CF - R. Tarran (US)	
	Defective airway gland secretion in CF - J. Wine (US)	
	Ca ²⁺ activated Cl ⁻ secretion - how much does it contribute? - K. Kunzelmann (DE)	
	The Mucus Perspective - G. C. Hansson (SE)	
Thursday, June 12		
	Symposium 5	Meeting Hall 1
10:30-12:00	Freedom from pain and suffering - Effective Interventions Moderators: S. Ravilly (FR) / A. Tijtgat (BE)	
	Non pharmacological approaches - M. Bryon (UK)	
	Pharmacological approaches - H. Heijerman (NL)	
	Atraumatic nursing care in the CF Centre - F. Festini (IT)	
	Palliative care - K. Urch (UK)	
Thursday, June 12		
	Poster Session 1: Genetics / Registry: CF around the world	Terrace 1 and 2
	Moderators: M. Wilschanski (IL) / O. Cinek (CZ)	
	Abstract 49: First results of Newborn screening program for CF in Russia - N. Kashirskaya (RU)	
	Abstract 47: Newborn Screening for cystic fibrosis in the eastern part of saxonia - J. Hammermann (DE)	
	Abstract 48: First year of Polish National CF Newborn Screening - D. Sands (PL)	
	Abstract 43: Cascade carrier testing for cystic fibrosis: an Australian experience - B. McClaren (AUS)	
	Abstract 21: Genotypes and borderline sweat tests in Irish CF patients: an update - C. King (IE)	
	Abstract 29: Results of molecular-genetic testing of the CFTR gene mutations in Western Ukraine - H. Makukh (UA)	

Version (updated 3/14/2008)

	Abstract 33: CFTR gene mutations in IRT/DNA Cystic Fibrosis newborn screening in Poland. – A. Sobczynska-Tomaszewska (PL)	
	Abstract 457: Epidemiology of cystic fibrosis of the Omani population in the North Al Bathina region in Oman – H. Al Badi (OM)	
	Abstract 458: The prognosis of cystic fibrosis in the Western Cape province of South Africa: a 33 year study. – A. Westwood (ZA)	
	Abstract 456: Cystic fibrosis in the Czech Republic – V. Vavrova (CZ)	
12:00-14:30	Lunch	
13:30-14:30	Guided Poster Tours in the following categories: GI/Nutrition/Metabolic complications Microbiology Physiotherapy	
13:30-14:30	ECFS/EuroCareCF CF Registry Steering Committee	North Hall
13:30-14:30	ECFS Aging Group Meeting	Panorama Hall
13:30-14:30	International Psychosocial Study on Depression – Update meeting	Meeting Hall 1
Thursday, June 12		
14:30-16:00	Workshop 1	Panorama Hall
	Adherence: an old problem, new ideas	
	Moderators: G. Ullrich (DE) / D. Kadosh (IL)	
14:30	Introduction	
14:35 – 14:50	Abstract 392: An experiential approach to understanding adherence in CF – B. Ashby (UK)	
14:50 – 15:05	Abstract 391: Concordance and perceived benefits in patients with cystic fibrosis using dossett boxes – M. Williams-Gunn (UK)	
15:05 – 15:20	Abstract 412: Pathways Home Project: a pilot study of chronic disease self management in Cystic Fibrosis (CF) - M. Jessup (AUS)	
15:20 – 15:35	Abstract: 390 Improving clinic attendance – J. Walker (UK)	
15:35 – 15:50	Abstract 378 - Home tube feeding in adults with Cystic Fibrosis: Do patients really do it? – R. Chinuck (UK)	
15:50	Summary and Wrap-up	
Thursday, June 12		
14:30-16:00	Workshop 2	North Hall
	Impact of Mutations on CFTR Structure and on Interacting Proteins	
	Moderators: P. Lehn (FR) / A. Mehta (UK)	
	Overview: P. Lehn (FR)	
	Abstract 60: Insights into the structural features of the full length CFTR protein – I. Callebaut (FR)	
	Abstract 62: CFTR missing the first four transmembrane segments enhances wild type and $\Delta F508$ CFTR processing. - L. Cebotaru (USA)	
	Abstract 63: The revertant mutants G550E and 4RK alter the processing efficiency and gating behaviour of the CF mutant G551D – D. Sheppard (UK)	
	Abstract 65: The role of butyrate in CFTR-ENaC interactions – M. Duszyk (CDN)	
	Abstract 66: Annexin A5 increases the cell surface expression and the chloride channel function of the $\Delta F508$ -cystic fibrosis transmembrane regulator. – P. Trouvé (FR)	
	Abstract 67: SUMOylation is necessary for CFTR trafficking – C. Schulze (DE)	

Version (updated 3/14/2008)

Thursday, June 12		
14:30-16:00	Workshop 3	Meeting Hall 1
	Endocrine Complications in Cystic Fibrosis	
	Moderators: M. Ballmann (DE) / I. Ketchell (UK)	
	Abstract 343: Effect of Impaired Glucose Tolerance on Clinical Status in Adult CF Patients – H. Miller (UK)	
	Abstract 336: Impaired glucose metabolism in patients with CF during acute exacerbations – N. Nezer (IL)	
	Abstract 344: Is presence of cystic fibrosis-related diabetes really associated with a faster decline in pulmonary functions? – J. M. van den Berg (NL)	
	Abstract 335: Prevalence of cystic fibrosis related diabetes (CFRD) and its microvascular complications in an adult CF population – M. Choudhury (UK)	
	Abstract 352: Renal impairment in the adult cystic fibrosis population – S. King (AUS)	
	Abstract 353: Testosterone deficiency in adult males with cystic fibrosis – M. F. Katz (USA)	
Thursday, June 12		
14:30-16:00	Workshop 4	Congress Hall
	Quantification of severity of lung disease	
	Moderators: S. Elborn (UK) / L. Fila (CZ)	
	Abstract 254: Sample size estimation for CF clinical trials using rate of lung function decline (RLFD) as an efficacy endpoint – D. R. VanDevanter (USA)	
	Abstract 246: Long-term monitoring of Lung Clearance Index (LCI) in children with CF - F. Aljassim (SE)	
	Abstract 236: Quantitative cough assessment in cystic fibrosis (CF) – E. Kerem (IL)	
	Abstract 241: Walking distance as an outcome of antibiotic course in patients with cystic fibrosis – G. Pisi (IT)	
	Abstract 235: Volumetric ultra low dose expiratory computed tomography scans could be sufficient to monitor CF lung disease – M. Loeve (NL)	
	Abstract 320: Gastroesophageal reflux and aspiration in CF patients – D. Sifrim (BE)	
Thursday, June 12		
14:30-16:00	Workshop 5	Forum Hall
	New Therapies treating the basic defect	
	Moderators: M. Mall (DE) / L.J. Galletta (IT)	
	Abstract 87: PTC124 Induces CFTR Full-length Production and Activity in Children with Nonsense-Mutation-Mediated CF – I. Sermet-Gaudelus (FR)	
	Abstract 88: PTC124 Treatment over 3 Months Improves Pharmacodynamic and Clinical Parameters in Patients with Nonsense-Mutation-Mediated CF – M. Wilschanski (IL)	
	Abstract 89: MOLI1901 (Duramycin) increases chloride transport in Cystic Fibrosis airway epithelial and pancreatic cell lines – I. Oliynik (SE)	
	Abstract 90: Safety, tolerability and efficacy of multiple doses of aerosolised Moli1901 in adolescents and adults with cystic fibrosis – E. Eber (AT)	
	Abstract 91: Preventive but not late amiloride therapy reduces morbidity and mortality of cystic fibrosis-like lung disease in mice – D. Treis (DE)	
	Abstract 94: β -adrenergic stimulation alters sweat gland	

Version (updated 3/14/2008)

	potential difference in Cystic Fibrosis (CF) patients but not healthy controls – T. Gonska (CA)	
Thursday, June 12		
14:30-16:00	Poster Session 2: Microbiology: Basics to bedside	Terrace 1 and 2
	Moderators: M. Denton (UK) / A. Reimann (DE)	
	Abstract 131: Fluctuations in phenotypes and genotypes within populations of <i>Pseudomonas aeruginosa</i> during pulmonary exacerbations in Cystic Fibrosis – J. Fothergill (UK)	
	Abstract 134: <i>Pseudomonas aeruginosa</i> with a specific OprD type predominantly present in chronically infected CF patients – P. Deschaght (BE)	
	Abstract 142: Microbiologic resistance and clinical efficacy of aztreonam lysine for inhalation (AZLI) in cystic fibrosis (CF) – K. McCoy (USA)	
	Abstract 151: Biofilm formation and antimicrobial susceptibility of <i>P. aeruginosa</i> isolates cultured before and after antibiotic treatment of an acute exacerbation of pulmonary infection – D. Gilpin (UK)	
	Abstract 155: Proteins released from <i>Pseudomonas aeruginosa</i> (Pa) referent and clinical strains under microaerobiosis and their effects on cystic fibrosis airways. – G. Bergamini (IT)	
	Abstract 156: Detection of low <i>Pseudomonas aeruginosa</i> colonization by real time polymerase chain reaction – M. O. Husson (FR)	
	Abstract 157: Detection of <i>Ps. aeruginosa</i> in paediatric Cystic Fibrosis patients is enhanced by modern molecular laboratory techniques – E. McCulloch (UK)	
	Abstract 160: Comparison of culture and molecular methods for detection and quantitation of aerobic and anaerobic bacteria in sputum from Cystic Fibrosis patients – M. Wolfgang (US)	
	Abstract 191: Clinical value of <i>aspergillus</i> detection in sputum obtained from 84 patients with cystic fibrosis – S. Chevrier (FR)	
16:00-16:30	Coffee	Exhibition Hall
Thursday, June 12		
16:30-18:00	Workshop 6	Congress Hall
	Large-Scale Modifier Gene Studies	
	Moderators: C. Férec (FR) / A. Mehta (UK)	
	CF Liver Disease – M. Knowles (US)	
	Diabetes in CF – G. Cutting (US)	
	Results from the Canadian CF Modifier Study – J. Zielenski (CA)	
	Sib/Twin analyses updated 2007 – B. Tümmler (DE)	
	Discussion panel	
Thursday, June 12		
16:30-18:00	Workshop 7	North Hall
	Virulence factors and pathogenesis	
	Moderators: N. Højby (DK) / P. Drevinek (CZ)	
	Abstract 148: Virulence of mucoid <i>Pseudomonas aeruginosa</i> strains in cystic fibrosis: New sequential infection model – C. Moser (DK)	
	Abstract 150: The paranasal sinuses are focus for colonisation and chronic biofilm lung infection in CF patients – H. K. Johansen (DK)	
	Abstract 149: Respiratory Syncytial Virus enhances <i>Pseudomonas aeruginosa</i> lung infection in mice – A. M. de Vrankrijker (NL)	
	Abstract 133: Genome sequence of a cystic fibrosis epidemic	

Version (updated 3/14/2008)

	strain of <i>Pseudomonas aeruginosa</i> - C. Winstanley (UK)	
	Abstract 154: Origin of lactate in CF sputum - D. Worlitzsch (DE)	
	Abstract 168: Invasion of <i>Burkholderia cepacia</i> complex isolates into lung epithelial cells involves glycolipid receptors - S. McClean (IE)	
Thursday, June 12		
16:30-18:00	Workshop 8	Meeting Hall 1
	Exercise in CF	
	Moderators: J. Bradley (UK) / L. Smolikova (CZ)	
	Abstract 288: Attitudes to Recreational Androgenic Anabolic Steroids among Adult CF Patients - A. Morris (UK)	
	Abstract 289: Pelvic floor muscle training in adolescent females with cystic fibrosis - J. Depiazzi (AU)	
	Abstract 290: Developing a musculoskeletal service for adults with cystic fibrosis - M. Ruane (UK)	
	Abstract 291: Only a few osteoporotic adult CF patients and no vertebral fractures - L. Lannefors (SW)	
	Abstract 238: Working capacity and oxygen uptake in CF - M. Gilljam (SE)	
	Abstract 292: First results of five year follow-up of exercise capacity in Belgian CF-children: what do they tell us for the future? - M. Vreys (BE)	
18:15 - 19:15	Registry	North Hall
Thursday, June 12		
16:30-18:00	Workshop 9	Forum Hall
	Complications in CF: What can we learn - and not learn - from the registries	
	Moderators: D. Tjesic-Drinkovic (HR) / M. Stern (DE)	
	CFRD - which data would be beneficial for further research - D. Hubert (FR)	
	Liver disease - which data would be beneficial for further research - A. Lindblad (SE)	
	Abstract 450: Disadvantage for patients over 24 months at diagnosis of cystic fibrosis - I. de Monestrol (SE)	
	Abstract 453: Clear illustration of improved survival in CF: the experience of Brittany (France) - V. Scotet (FR)	
	Abstract 455: Forty years isolation from W. Europe and its influence on the course of CF: an unwanted experiment - D. Zemkova (CZ)	
Thursday, June 12		
16:30-18:00	Workshop 10	Panorama Hall
	Selected clinical issues in nursing and psychosocial practice	
	Moderators: K. De Rijcke (BE) / T. Tesarova (CZ)	
16:30	Introduction - K. De Rijcke (BE)	
16:35 - 16:50	Abstract 404: Striving for glycaemic control in cystic fibrosis related diabetes: A qualitative study - S. Tierney (UK)	
16:50 - 17:05	Abstract 401: Optimal delivery of end of life care for CF patients, families and staff - M. Braithwaite (AU)	
17:05 - 17.20	Abstract 400: Quality of life in women with cystic fibrosis and urinary incontinence - P. Agent (UK)	
17.20 - 17.35	Abstract 403: Prevalence of passive exposure to cigarette and active smoking in a large pediatric CF centre in Montreal (Québec, Canada) - S. Laberge (CA)	
17.35 - 17.50	Abstract 479: A 5-year retrospective study of totally implantable ports in CF patients. - E. De Wachter (BE)	
17:50	Summary and wrap-up	

Version (updated 3/14/2008)

Thursday, June 12		
16:30-18:00	Poster Session 3: Pulmonology / New Therapies	Terrace 1 and 2
	Moderators: J. Brazova (CZ)/ S. Bell (AUS)	
	Abstract 271: Invasive mechanical ventilation a risk factor for death in patients with Cystic Fibrosis admitted to intensive care unit - Outcome and prolongs follow up. - O. Efrati (IL)	
	Abstract 280: CF Pediatric Lung Transplantation Single Center Experience - R. Souilamas (FR)	
	Abstract 141: Cost analysis of treatment for <i>Pseudomonas aeruginosa</i> infection in cystic fibrosis patients - G. Taccetti (IT)	
	Abstract 93: Hypertonic Saline: Effect on Mucus Rheology and Spirometry - N. De Cono (BE)	
	Abstract 218: Potential role of EPI-hNE4 treatment in CF patients - V. Prulière-Escabasse (FR)	
	Abstract 103: Pharmacokinetics of Ciprofloxacin PulmoSphere® Inhalational Powder - H Stass (UK)	
	Abstract 107: Sinu-nasal inhalation of Dornase alfa in CF. Results of a double-blind-placebo controlled pilot-trial - J. Mainz (DE)	
	Abstract 255: Adherence to nebulised therapies for <i>Pseudomonas</i> eradication in a paediatric CF population - P. McCormack (UK)	
	Abstract 257: Eradication of recent <i>Pseudomonas aeruginosa</i> isolation: TOBI versus Colistin/Ciprofloxacin - M. Proesmans (BE)	
Friday, June 13		
07:30-08:30	Journal of Cystic Fibrosis Editorial Board Meeting	Club Room
07:30-08:15	Round tables	Terraces 1 and 2
	Aging in CF - from the physiotherapy Perspective	B. Button (AU)
	The role of the Nurse in the CF Team	D. Sheehan (UK)
	Using Patient Drawings in Clinical Practice	D. Khadosh (IL)
	Implementation of QoL in registries	J. Abbot (UK)
	Experience with PortCF	A. Lindblad (SE)
	CF and hygiene in the home, too little, too much	M. Denton (UK)
	Anti-fungal treatment	C. Knoop (BE)
	Paediatric lung transplant	C. Benden (CH)
	Pulmonary function testing in infants and young children	S. Ranganathan (AUS)
	Management of sinus disease	M. Hodson (UK)
	Pitfalls with CF neonatal screening programme	I. Doull (UK)
	Mutation Specific Therapies	B. Kerem (IL)
	Abdominal Pain in CF	J. Walkowiak (PL)
	Nutritional Assessment in CF	A. Morton (UK)
	Non-tuberculous mycobacteria	B. Fauroux (FR)
	Cross-infection and segregation in and out of hospital	J. Govan (UK)
	<i>Pseudomonas</i> antibody - diagnostic use	T. Pressler (DK)
	Host-Pathogen Interactions	P. Sokol (CDN)
	CFTR interacting proteins: the devil is in the detail?	M. Amaral (PT)
Friday, June 13		
	Symposium 6	Congress Hall
08:30-10:00	New Therapies: Tailored therapies for CF mutations	
	Moderators: C. De Boeck (BE) / D. Sheppard (UK)	
	NMD: basic science and clinical aspects - B. Kerem and E. Kerem (IL)	
	CFTR correctors - F. Van Goor (US)	
	CFTR potentiators - L. Galletta (IT)	
	Drugs to improve mucociliary clearance - M. Knowles (US)	

Version (updated 3/14/2008)

Friday, June 13		
	Symposium 7	Panorama Hall
08:30-10:00	Hepatobiliary Disease in CF	
	Moderators: C. Colombo (IT) / TBD (CZ)	
	The fatty liver in CF – B. Strandvik (SE)	
	Ultrasound screening for liver disease in CF – L. Stewart (UK)	
	Is ursodeoxycholic acid effective in arresting the natural history of hepatic disease? – C. Colombo (IT)	
	Long Term complications, medical management and transplantation – D. Debray (FR)	
Friday, June 13		
	Symposium 8	North Hall
08:30-10:00	Grand rounds in pulmonary disease	
	Moderators: H. Heijerman (NL)	
08:30-08:45	Successful treatment of non-tuberculous mycobacterial infection with interferon gamma - A McKee (UK)	
08:45-09:00	Pulmonary infection with multiresistant M. Abscessus, a remarkable recovery – J. Daflaar (NL)	
09:00-09:15	Balancing Hope with Reality: A case of systemic melioidosis in cystic fibrosis – D. Forrester (UK)	
09:15-09:30	Cepacia syndrome and a large chest wall mass: a clinical challenge – N. Simmonds (UK)	
09:30-09:45	Wangiella (Exophiala) dermatitidis in Cystic Fibrosis: Colonization or Infection? Some answers from a CF-patient – A. Jeanneret (CA)	
09:45-10:00	CF and single lung transplantation - P. Cifelli (UK)	
	Best Case Presentation Award by Expert Panel	
Friday, June 13		
	Symposium 9	Forum Hall
08:30-10:00	Physiology of Airway Clearance	
	Moderators: M. McIlwaine (CA) / L. Smolikova (CZ)	
	Enhancing mucociliary clearance in CF - M. Elkins (AU)	
	Changes in ventilation in CF: What can we do about it? - B. Button (AU)	
	Expiratory Resistance Breathing - L. Lannefors (SE)	
	Optimizing airflow velocity - J. Chevallier (BE)	
Friday, June 13		
	Symposium 10	Meeting Hall 1
08:30-10:00	Quality indicators and patient satisfaction	
	Moderators: M. Bryon (UK) / L. Goldbeck (DE)	
	Patient reported outcome: Concepts and measures – A. Quittner (US)	
	Results from quality of life studies – J. Abbot (UK)	
	Quality assessment in practice – H. Ellemunter (AT)	
	Patient satisfaction – B. Holzer (CH)	
10:00-10:30	Coffee	Exhibition Hall
Friday, June 13		
	Symposium 11	Congress Hall
10:30-12:00	Data from European Registries	
	Moderators: L. Foley (IE) / M. Macek (CZ)	

Version (updated 3/14/2008)

	Data from European Registry: New arrivals versus old hands – M. Macek (CZ)	
	"Celtic" Mutations, New assays and Newborn Screening – D. Barton (IE)	
	ECFS Data – H. Olesen (DK) / B. Wiedemann (DE)	
	Patients > 40 years old – J. McCormick (UK)	
Friday, June 13		
	Symposium 12	North Hall
10:30-12:00	CFTR (Dys)functions	
	Moderators: K. Kunzelmann (DE) / M. Amaral (PT)	
	Mutant CFTR: a Dysfunctional Cl ⁻ channel – D. Sheppard (UK)	
	Ion Transport in CF has Multiple Defects – M. Chanson (CH)	
	Defective apical endocytosis in CF – O. Devuyt (BE)	
	How important is adherence of <i>P. aeruginosa</i> to CFTR? – T. J. Evans (UK)	
Friday, June 13		
	Symposium 13	Forum Hall
10:30-12:00	Inhaled Medications and Devices	
	Moderators: M. Schoeni (CH) / I. Eichler (AT)	
	Proceedings of the 2008 Consensus Meeting	
Friday, June 13		
	Symposium 14	Meeting Hall 1
10:30-12:00	Anti-infective therapies	
	Moderators: M. Denton (UK)/ O. Nyc (CZ)	
	Optimal PK/PD use of current antibiotics – D. Touw (NL)	
	Early eradication of CF pathogens – T. Lee (UK)	
	What is in the clinical pipeline – J. Burns (USA)	
	New therapy of biofilm infection – M. Givskov (DK)	
Friday, June 13		
	Symposium 15	Panorama Hall
10:30-12:00	Nutritional Support of the CF Patient	
	Moderators: A. Munck (FR) / H. McCabe (UK)	
	Assessment of the nutritional status of the patient with cystic fibrosis – A. Munck (FR)	
	Enteral tube feeding to meet nutritional requirements – R. Watling (UK)	
	Age related eating disorders – S. Wolfe (UK) / A. Duff (UK)	
	When Enteral nutrition support is not enough – S. King (AU)	
12:00-14:30	Lunch	
13:30-14:30	Guided Poster Tours in the following categories: Screening/Diagnosis/Genetics CFTR/Cell Biology/Physiology Psychosocial Issues/ Nursing	
13:30-14:30	ECFS Neonatal Screening Working Group Meeting	North Hall
Friday, June 13		
	Workshop 11	Forum Hall
14.30-16.00	Novel Treatments for pulmonary disease in CF	

Version (updated 3/14/2008)

	Moderators: B. Fauroux (FR) / H. Heijerman (NL)	
	Abstract 100: Effect of multiple Aztreonam Lysine for Inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and <i>Pseudomonas aeruginosa</i> (PA): Interim analysis of 12 month data – C. Oermann (USA)	
	Abstract 102: A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace™) in the treatment of cystic fibrosis patients with chronic <i>Pseudomonas aeruginosa</i> lung infection – L. Dupont (BE)	
	Abstract 101: Inhaled tobramycin nebulizer solution for treatment of early <i>Pseudomonas aeruginosa</i> infection: the ELITE study – F. Ratjen (CDN)	
	Abstract 98: Use of Azithromycin in cystic fibrosis patients not infected with <i>Pseudomonas Aeruginosa</i> . – B. O'Connor (UK)	
	Abstract 230: Intravenous Methylprednisolone Pulse Therapy vs. Oral Prednisone for Allergic Bronchopulmonary Aspergillosis (ABPA) in CF – M. Cohen-Cyberknoh (IL)	
	Abstract 281: Fifteen years of lung transplantation (LTx) in patients with cystic fibrosis (CF): The Zurich experience – M. Hofer (CH)	
Friday, June 13		
	Workshop 12	Congress Hall
14:30-16:00	GI Case Presentations	
	Moderators: B. Strandvik (SE) / J. Walkowiak (PL) / C. Taylor (UK)	
14:30-14:45	An Unusual Presentation of Distal Intestinal Obstruction Syndrome following Lung Transplantation in a Patient with Cystic Fibrosis – G. Frazer (NZ)	
14:45-15:00	'Passing Seaweed' – an unusual complication of a common problem – S. Srivastava (UK)	
15:00-15:15	Gastric dysmotility and failure to thrive in a child with cystic fibrosis – S.P. Jerkic (UK)	
15:15-15:30	Severe nutritional challenges post complicated MI - R. Huggins (UK)	
15:30-15:45	Cystic fibrosis infant with severe ischemic colitis. A diagnostic dilemma – A. Hollsing (SE)	
15:45-16:00	Diagnosis of cystic fibrosis in a four-months-old boy with acute liver failure – U. Graepler-Mainka (DE)	
	Best Case Presentation Award by the Panel	
Friday, June 13		
	Workshop 13	North Hall
14.30-16.00	CFTR: From molecular to tissue function	
	Moderators: M. Conese (IT) / D. Nelson (US)	
	Overview: M. Gray (UK)	
	Abstract 79: Inflammation and abnormal tissue remodeling in F508del mutant mice. – B. Scholte (NL)	
	Abstract 80: Transcriptional profile of human airway cells during the epithelial regeneration – C. Coraux (FR)	
	Abstract 72: The CD73/adenosine pathway regulates gap junctional intercellular communication in the CFTR-expressing Calu-3 airway cell line – L. K. Scheckenbach (CH)	
	Abstract 68: Renal cyst formation as tool for CFTR research – H. Li (UK)	
	Abstract 77: Regulation of the KCa3.1 channel by AMP-activated protein kinase in Cl ⁻ secreting cells – R. Sauvé (CA)	
	Abstract 75: Nicotinic receptor $\alpha 7$ regulates CFTR-dependent ion transport in the airway epithelium – J.M. Tournier (FR)	
Friday, June 13		

Version (updated 3/14/2008)

	Workshop 14	Panorama Hall
14:30-16:00	QoL in registries	
	Moderators: T. Havermans (BE) / H. Olesen (DK)	
	Experience with QoL in the German Registry – D. Staab (DE)	
	CFQ and socioeconomic determinants – H. Janssen (BE)	
	Social factors and keys to intervention – H. Von der Hardt (DE)	
	Abstract 452: Development of a patient-reported outcome measure in adult cystic fibrosis – M. S. Salek (UK)	
	Abstract 268: Quality of life in people with Cystic Fibrosis whilst clinical stable – S. Bell (AUS)	
Friday, June 13		
	Workshop 15	Meeting Hall 1
14.30-16.00	New trends in Physiotherapy	
	Moderators: L. Van der Giessen (NL) / F. Van Ginderdeuren (BE)	
	Introduction – L. Van der Giessen (NL)	
	Abstract 295: High frequency chest wall oscillation in cystic fibrosis – J. Pryor (UK)	
	Abstract 310: A proactive approach pays off in screened infants with CF – K. Sharp (UK)	
	Abstract 300: Short term improvement of pulmonary function tests following airway clearance using the TRI-GYM™ Breathing Exercisers – G. Sokol (IL)	
	Abstract 285: Influence of inhaled hypertonic saline, combined with airway clearance on SpO ₂ , heart rate, dyspnoea and wet sputum weight in hospitalised CF patients. – S. Vanlaethem (BE)	
	Abstract 286: Use and perceived benefits of nebulised hypertonic saline (HS) treatment in adult patients with cystic fibrosis – V. Gettins (UK)	
16:00-16:30	Coffee	Exhibition Hall
Friday, June 13		
	Workshop 16	Forum Hall
16:30-18:00	Late Breaking science	
	Moderators: H. Cuppens (BE) / M. Amaral (PT)	
	Overview (including news from the 2008 Basic Science Conference) – K. Kunzelmann (DE)	
	2 Invited speakers (to be announced at a later stage)	
	2 more talks from Abstracts	
Friday, June 13		
	Workshop 17	Meeting Hall 1
16:30-18:00	Focus on Inflammation	
	Moderators: G. Döring (DE) / V. Vavrova (CZ)	
	Abstract 215: Lack of control of <i>Pseudomonas aeruginosa</i> pulmonary infection in the absence of recognition of both lipopolysaccharide and flagellin. – M. Chignard (FR)	
	Abstract 216: The respiratory burst of PMNs accelerates anaerobiosis in sputum from CF patients with chronic <i>Pseudomonas aeruginosa</i> lung infection – P. Ø. Jensen (DK)	
	Abstract 221: Elevated IL-17 and IL-23 mRNA levels in sputum of stable CF patients – A. Decraene (BE)	
	Abstract 223: A new candidate biomarker of inflammation in CF airway: Amphiregulin – J. Jacquot (FR)	
	Abstract 214: Azithromycin is not able to decrease inflammatory process in cystic fibrosis cells – V. Saint-Criq (FR)	
	Abstract 208: Immunomodulatory properties of vitamin D in	

Version (updated 3/14/2008)

	Scandinavian cystic fibrosis patients - T Pincikova (SE)	
Friday, June 13		
	Workshop 18	North Hall
16.30-18.00	Genetics and screening	
	Moderators: B. Kerem (IL) / A. Stambergova (CZ)	
	Abstract 44: A French collaborative study indicative of a very low classical-CF penetrance of R117H; implications for genetic counselling – E. Girodon (FR)	
	Abstract 24: Occurrence of CFTR de novo mutations is not so rare – M.P. Audrezet (FR)	
	Abstract 12: Do in silico tools predict the clinical consequences of CFTR missense mutations? – R. Dorfman (CA)	
	Abstract 37: Intestinal current measurement for difficult CF diagnosis: reference values and reproducibility – N. Derichs (DE)	
	Abstract 2: The β -defensin region affects CF lung disease severity – H. Nuytten (BE)	
	Abstract 1: ENaC mutations in patients with CF-like disease – H. Cuppens (BE)	
Friday, June 13		
	Workshop 19	Panorama Hall
16:30-18:00	Infection Control	
	Moderators: J. Govan (UK) / J. Bartosova (CZ)	
	Abstract 115: First European CF Microbiology Quality Assurance Trial – B. Tümmler (DE)	
	Abstract 118: Are transmissible strains of <i>Pseudomonas aeruginosa</i> associated with increased morbidity and mortality for patients with CF? – A. Jones (UK)	
	Abstract 123: Characterization of <i>Pseudomonas Aeruginosa</i> (PA) recovered from swimming pools and from Italian Cystic Fibrosis (CF) patients. – P. Morelli (IT)	
	Abstract 116: Patient-to-patient transmission of a multiresistant <i>Pseudomonas aeruginosa</i> strain in a summer camp detected by prospective follow up. – F. Karpati (SE)	
	Abstract 124: Is the 1-meter distance enough to prevent cross-infection in cystic fibrosis? Preliminary results of a prospective study – F. Festini (IT)	
	Abstract 179: Water filters can prevent <i>Stenotrophomonas maltophilia</i> contamination of nebulizer equipment used by people with cystic fibrosis (CF) – M. Denton (UK)	
Friday, June 13		
	Workshop 20	Congress Hall
16:30-18:00	Psychosocial and Nursing complex case presentations and responses	
	Moderators: S. Madge (UK) + Expert Panel (Jane de Vries (NL) - Nurse; Anne Calvert (UK) - Social Worker; Trudy Havermans (BE) - Psychologist	
16:30-16:51	The Two faces of A - I. Krug (DE)	
16:51-17:12	A CF pregnancy against all odds? – K. Colpaert (BE)	
17:12-17:33	Fighting CF - a way of coping or failure to adapt? – H. Oxley (UK)	
17:33-17:54	Case Study – M. van Hattem (NL)	
17:54-18:00	Wrap up and Case Presentation Award by Expert Panel	
Friday, June 13		
16:30-18:00	Poster Session 4: GI Nutrition	Terrace 1 and 2
	Moderators: H. McCabe (UK)/ J. Walkowiak (PL)	

Version (updated 3/14/2008)

	Abstract 322: Constipation in pediatric Cystic Fibrosis patients: an underestimated medical condition. – H. van der Doef (NL)	
	Abstract 321: Enteropathy - A new finding in Cystic Fibrosis – M. Wilschanski (IL)	
	Abstract 325: The effect of tegaserod in patients with distal intestinal obstruction syndrome – I. Gooding (UK)	
	Abstract 323: Defining DIOS and Constipation in Cystic Fibrosis: A multicenter study on the incidence, characteristics and treatment of DIOS - – H. van der Doef (NL)	
	Abstract 360: Nutritional status, body composition and exercise capacity in children with cystic fibrosis – K. Rylance (UK)	
	Abstract 382: Impact of aggressive nutritional intervention on early and late acquisition of CFRD in an adult population? – H. White (UK)	
	Abstract 374: Linoleic acid but not EPA and DHA correlates to prognostic markers in Scandinavian CF patients - L. Hjelte (SE)	
	Abstract 375: Clinical effect of long term oral DHA supplementation in Cystic Fibrosis patients – S. Van Biervliet (BE)	
	Abstract 354: Pilot study on the effects of lycopene on oxidation and fatty acids in CF patients.- G Wojewodka (CA)	
	Abstract 346: Loss of lean tissue mass in adults with CF: an independent predictor of loss of bone mineral density (BMD) – S. King (AU)	
18:00-19:30	EuroCareCF Workpackage 1 Meeting	North Hall
20:30	Conference Dinner & Party	
Saturday, June 14		
09:00-10:30	Symposium 16	Forum Hall
	Transplantation	
	Moderators: P. Corris (UK) / J. Simonek (CZ)	
	Recent advances in Lung Transplantation for Adult CF – P. Corris (UK)	
	Paediatric Lung Transplantation State of the Art and Science – C. Benden (CH)	
	Gastro Oesophageal Reflux and lung Transplantation – L. Dupont (BE)	
	Emerging Infective Threats following Lung Transplantation for CF – M. Hannan (IE)	
Saturday, June 14		
	Symposium 17	North Hall
09:00-10:30	Quality Improvement in CF	
	Moderators: B. Marshall (US) / A. Mehta (UK)	
	Is there a real difference between centres – A. Mehta (UK)	
	CF Benchmarking in USA – M. Schechter (US)	
	Benchmarking using international registry data – C. De Boeck (BE)	
	CF Benchmarking in Germany - M. Stern (DE)	
Saturday, June 14		
	Symposium 18	Congress Hall
09:00-10:30	Mechanisms of early pulmonary disease	
	Moderators: G. Döring (DE) / V. Vavrova (CZ)	
	Early Disease Surveillance – P. Sly (AU)	

Version (updated 3/14/2008)

	Remodeling in the CF Airway – P. Pohunek (CZ)	
	Consequences of ceramide accumulation – E. Gulbins (GE)	
	Bacterial killing in CF – D. Nelson (US)	
Saturday, June 14		
	Symposium 19	Meeting Hall 1
09:00-10:30	Consensus in Screening and Diagnosis	
	Moderators: C. Castellani (IT) / V. Skalicka (CZ)	
	Neonatal Screening consensus-laboratory issues – C. Férec (FR) / G. Travert (FR)	
	Neonatal Screening consensus-clinical & diagnostic issues – K. Southern (UK)	
	New North-American Guidelines for Diagnosis – P. Farrell (US)	
	Consensus on use and interpretation of mutation analysis in the clinical setting – C. Castellani (IT)	
Saturday, June 14		
	Symposium 20	Panorama Hall
09:00-10:30	Communication: Understanding and Misunderstanding	
	Moderators: F. Festini (IT) / K. De Rijcke (BE)	
	Parent-child interaction – A. Tluczek (US)	
	How to communicate with your patients – breaking bad news – G. Ullrich (DE)	
	Team communication: values, roles, and respect – S. Madge (UK)	
	Motivational interviewing – A. Duff (UK)	
10:30-11:00	Coffee	Exhibition Hall
Saturday, June 14		
		Congress Hall
11:00-12:30	Plenary II	
	Moderators: M. Macek (CZ) / New ECFS President	
	CFTR and Nutrition – The problem and some solutions – D. Borowitz (US)	
	This year in review – What have we learnt? – D. Sheppard (UK)	
	ECFS President – 20 minutes	
12.30-13.00	Closing Ceremony	Congress Hall
14:00-18:30	Scientific Committee Meeting – Brest 2009	Room location: TBD